These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30303528)

  • 21. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Augmented Intelligence for Pharmacovigilance Case Seriousness Determination.
    Routray R; Tetarenko N; Abu-Assal C; Mockute R; Assuncao B; Chen H; Bao S; Danysz K; Desai S; Cicirello S; Willis V; Alford SH; Krishnamurthy V; Mingle E
    Drug Saf; 2020 Jan; 43(1):57-66. PubMed ID: 31605285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.
    Kassekert R; Grabowski N; Lorenz D; Schaffer C; Kempf D; Roy P; Kjoersvik O; Saldana G; ElShal S
    Drug Saf; 2022 May; 45(5):439-448. PubMed ID: 35579809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artificial Intelligence for Drug Toxicity and Safety.
    Basile AO; Yahi A; Tatonetti NP
    Trends Pharmacol Sci; 2019 Sep; 40(9):624-635. PubMed ID: 31383376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance.
    Yang CC; Yang H
    Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promoting adverse drug reaction reporting: comparison of different approaches.
    Ribeiro-Vaz I; Santos CC; Cruz-Correia R
    Rev Saude Publica; 2016; 50():14. PubMed ID: 27143614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
    Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
    Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards on-line ADR detection: an innovative data cube-based approach.
    Lin WY; Du JW
    Stud Health Technol Inform; 2013; 192():1218. PubMed ID: 23920992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.
    Zhang X; Niu R; Feng B; Guo J; Liu Y; Liu X
    Expert Opin Drug Saf; 2019 Jan; 18(1):59-68. PubMed ID: 29883236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel data-mining methodologies for adverse drug event discovery and analysis.
    Harpaz R; DuMouchel W; Shah NH; Madigan D; Ryan P; Friedman C
    Clin Pharmacol Ther; 2012 Jun; 91(6):1010-21. PubMed ID: 22549283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP
    Montastruc F; Bagheri H; Lacroix I; Damase-Michel C; Chebane L; Rousseau V; Jouanjus E; Lapeyre-Mestre M; Durrieu G; Montastruc JL
    Drug Saf; 2018 May; 41(5):511-514. PubMed ID: 29270770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of case reports in pharmacovigilance.
    Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
    Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
    [No Abstract]   [Full Text] [Related]  

  • 40. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.